Title : Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Pub. Date : 2021 Dec

PMID : 34526701






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The introduction of potent androgen receptor signalling inhibitors (ARSIs), such as abiraterone, apalutamide, enzalutamide and darolutamide, has led to a renewed interest in using neoadjuvant hormonal treatment in high-risk prostate cancer. apalutamide androgen receptor Homo sapiens